Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome
Authors
Keywords
Noonan syndrome, chylous effusion, chylous ascites, MEK inhibition, case series
Journal
JOURNAL OF PEDIATRICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-20
DOI
10.1016/j.jpeds.2022.05.030
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trametinib-based Treatment of Pediatric CNS Tumors
- (2020) Megan R. Paul et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation
- (2020) Yoav Dori et al. PEDIATRICS
- Imaging of central lymphatic abnormalities in Noonan syndrome
- (2019) David M. Biko et al. PEDIATRIC RADIOLOGY
- Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition
- (2019) Gregor Andelfinger et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor
- (2019) Dong Li et al. NATURE MEDICINE
- Cardiac transplantation in children with Noonan syndrome
- (2019) Leslie M. McCallen et al. PEDIATRIC TRANSPLANTATION
- A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
- (2019) Sébastien Perreault et al. BMC CANCER
- Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly
- (2018) Dong Li et al. HUMAN MOLECULAR GENETICS
- Octreotide for congenital and acquired chylothorax in newborns: A systematic review
- (2018) Carlo Bellini et al. JOURNAL OF PAEDIATRICS AND CHILD HEALTH
- Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells
- (2018) Sarah K. Tasian et al. LEUKEMIA
- FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers HarboringBRAF V600EMutations
- (2018) Lauretta Odogwu et al. ONCOLOGIST
- First trimester cystic hygroma colli: Retrospective analysis in a tertiary center
- (2018) Lore Schreurs et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- How I treat juvenile myelomonocytic leukemia
- (2015) F. Locatelli et al. BLOOD
- The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome
- (2015) Sarah Joyce et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Twin Infant with Lymphatic Dysplasia Diagnosed with Noonan Syndrome by Molecular Genetic Testing
- (2014) Deepan Mathur et al. Fetal and Pediatric Pathology
- Genetics of lymphatic anomalies
- (2014) Pascal Brouillard et al. JOURNAL OF CLINICAL INVESTIGATION
- Noonan syndrome
- (2013) Amy E Roberts et al. LANCET
- Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry
- (2012) James D. Wilkinson et al. AMERICAN HEART JOURNAL
- Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome
- (2012) Patroula Smpokou et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation
- (2011) Xue Wu et al. JOURNAL OF CLINICAL INVESTIGATION
- VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis
- (2010) Luqing Zhang et al. CELL RESEARCH
- H-, N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice
- (2010) T. Ichise et al. DEVELOPMENT
- Myeloproliferative Disorder in Noonan Syndrome
- (2010) Pilar Bastida et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- The tyrosine phosphatase Shp2 (PTPN11) in cancer
- (2008) Gordon Chan et al. CANCER AND METASTASIS REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now